MRVT Stock Overview

Operates as a pharmaceutical research and development company. More details

MRVT fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Shares are highly illiquid

Does not have a meaningful market cap ($37)

Latest financial reports are more than a year old

My Notes

Capture your thoughts, links and company narrative

Miravant Medical Technologies Inc. Competitors

PLx Pharma Winddown

OTCPK:PLXP.Q

US$30.0

Plant-Based Investment

OTCPK:CWWB.F

US$27.0

MJ Holdings

OTCPK:MJNE

US$58.0

Juva Life

OTCPK:JUVA.F

US$164.0

Price History & Performance

Summary of share price highs, lows and changes for Miravant Medical Technologies
Historical stock prices
Current Share Price	US$0.000001
52 Week High	US$0.000001
52 Week Low	US$0.000001
Beta	0
1 Month Change	0%
3 Month Change	n/a
1 Year Change	0%
3 Year Change	-99.97%
5 Year Change	0%
Change since IPO	-100.00%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	MRVT	US Pharmaceuticals	US Market
7D	0%	-0.6%	-0.2%
1Y	0%	3.0%	25.8%

Return vs Industry: MRVT underperformed the US Pharmaceuticals industry which returned 15.4% over the past year.

Return vs Market: MRVT underperformed the US Market which returned 20.5% over the past year.

Price Volatility

Is MRVT's price volatile compared to industry and market?
MRVT volatility
MRVT Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	10.8%
Market Average Movement	6.4%
10% most volatile stocks in US Market	18.6%
10% least volatile stocks in US Market	3.1%

Stable Share Price: MRVT has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine MRVT's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1989	n/a	n/a	n/a

Miravant Medical Technologies Inc. operates as a pharmaceutical research and development company. The company develops PhotoPoint, a photodynamic therapy that responds to light destroying cancerous cells; and manufactures light producing and light delivery devices. Its products include PHOTREX for the treatment of wet age-related macular degeneration or AMD; MV9411, a photoreactive drug for the treatment of plaque psoriasis; MV0633 for the treatment of atherosclerosis, atherosclerotic vulnerable plaque, and restenosis; MV2101 for the treatment of vascular access graft disease in hemodialysis patients; and MV6401 for the treatment of solid tumors.

Miravant Medical Technologies Inc. Fundamentals Summary

How do Miravant Medical Technologies's earnings and revenue compare to its market cap?
MRVT fundamental statistics
Market cap	US$37.00
Earnings (TTM)	-US$15.34m
Revenue (TTM)	n/a

0.0x

P/S Ratio

0.0x

P/E Ratio

Is MRVT overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
MRVT income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$15.34m
Earnings	-US$15.34m

Last Reported Earnings

Sep 30, 2005

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did MRVT perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/09/11 07:37
End of Day Share Price	2024/06/14 00:00
Earnings	2005/09/30
Annual Earnings	2004/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Miravant Medical Technologies Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution